BLUESTAR GENOMICS INC. (ClearNote Health)

Company Snapshot

Founded: 2016
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: North America
Corporate Address: 10578 Science Center Drive Suite 210, San Diego California 92121 U.S. Tel. +1-(833)-258-7827 www.clearnotehealth.com

Company Overview

Bluestar Genomics Inc. is developing epigenomics-based liquid biopsy diagnostics. The company is actively discovering epigenetic biomarkers for early-stage cancer applications.

Bluestar Genomics has a strong position in proprietary chemistries, bioinformatics and big data for next-generation sequencing.

The early detection of pancreatic cancer via cfDNA was shown to be possible by using a methylation biomarker, 5-hydroxymethylcytosine (5hmC).[23] The researchers concluded that, based on their data, 5hmC changes can allow for classification of PDAC (pancreatic ductal adenocarcinoma) even during early stages of the disease.

Bluestar Genomics is seeking to develop a liquid biopsy test for early-stage PDAC as well as early-stage, pan-cancer tests. The company intends to run these tests as LDTs out of an anticipated CLIA-certified laboratory in San Diego.

BLUESTAR GENOMICS INC. (ClearNote Health) In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

BCC Market Research Report for global liquid biopsy research tools, liquid biopsy biomarkers, technologies, services and diagnostics markets.

Company's Business Segments

  • Liquid Biopsy : The company helps in early detection data for clinicians and their patients having a high risk of developing high-mortality cancers.

Applications/End User Industries

  • Healthcare
  • Diagnosis
  • Life Sciences
AI Sentiment